Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance
Go back to Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 228.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $228.65 | 52 Week High | $109.10 | |||
| Open | $228.65 | 52 Week Low | $31.38 | |||
| Day High | $228.65 | P/E | N/A | |||
| Day Low | $228.65 | EPS | $-1.45 | |||
| Volume | 185 | |||||
